Australia: National Reconstruction Fund Corporation takes AUD 27 million equity stake in PolyActiva glaucoma-implant biotech

Mechanism

NRFC — the AUD 15 billion Commonwealth financing vehicle established to rebuild sovereign industrial capability — took a AUD 27 million minority equity position inside PolyActiva's AUD 40 million Series C round, announced 30 May 2025. PolyActiva, founded in 2010 and spun out of research at CSIRO, the Bionics Institute and the Centre for Eye Research Australia, has developed Prezia, a biodegradable sustained-release ocular implant (lead candidate PA5108) that delivers latanoprost to reduce intraocular pressure in glaucoma and ocular-hypertension patients over 6-12 months, replacing daily eye-drop regimens. The implant dissolves after drug delivery and can be replaced during routine follow-up care.

The round's remaining AUD 13 million came from existing investor Brandon Capital — this is PolyActiva's first major institutional raise since a AUD 9.5 million Series B in 2013. Proceeds will consolidate the company's R&D, analytics and manufacturing operations into a single Melbourne facility, grow its headcount from ~25 employees (plus 4 Monash University research contractors) by an initial 6 positions, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029. NRFC and CEO Vanessa Waddell frame the deal as keeping a globally significant medtech platform locally headquartered through to commercialisation rather than relocating or selling offshore, consistent with NRFC's broader onshoring mandate across its life-sciences and deep-tech portfolio.

Downstream implications

• Extends NRFC's pattern (alongside 2025-07-24-australia-nrfc-brandon-capital-medical-science-fund)

of anchoring life-sciences Series rounds to keep Australian-founded medtech IP and manufacturing onshore rather than exiting to larger offshore acquirers.

• A sovereign fund taking a majority share (67.5%) of a private Series C round is an unusually

concentrated position for NRFC relative to its other minority-equity plays — worth watching for governance/board-seat terms if disclosed later.

Open questions

• No public disclosure of board or governance rights NRFC holds as a majority-of-round investor.
• Unclear whether NRFC's stake carries any conditions tying continued funding to the Melbourne

facility consolidation or Phase 2b trial milestones.